#cytk

📰

Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (Rating Downgrade)

Seeking Alpha·Myriam Alvarez·25 days ago

Cytokinetics' aficamten recently met both primary endpoints in Phase 3 ACACIA-HCM for non-obstructive HCM. Read why CYTK stock is a Hold.

15s